National Trends in Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Glucagon‐like Peptide‐1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020

National Trends in Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Glucagon‐like Peptide‐1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020

Background Sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) mitigate cardiovascular risk in individuals with type 2 diabetes, but most eligible patients do not receive them. We characterized temporal trends in SGLT2i and GLP‐1RA use by card...

Full description

Bibliographic Details
Main Authors: Rishav Adhikari, Kunal Jha, Zeina Dardari, James Heyward, Roger S. Blumenthal, Robert H. Eckel, G. Caleb Alexander, Michael J. Blaha
Format: Article
Language:English
Published: Wiley 2022-05-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
cardiometabolic health
GLP‐1 receptor agonists
prescribing patterns
risk reduction
SGLT2 inhibitors
type 2 diabetes
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.121.023811

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.121.023811

Similar Items